Search This Blog

Thursday, May 15, 2025

Rubio asserts ‘peacemaker’ Trump sitting down with Putin is the ‘only’ way war in Ukraine ends

 Secretary of State Marco Rubio believes the “only way” the war in Ukraine ends is with President Trump — whom he described as a “lover of peace” — sitting across the table from Russian counterpart Vladimir Putin.

“I think that’s the only chance we have at peace at this point, given everything we’ve seen over the last few weeks,” Rubio told Fox News host Sean Hannity on Thursday, reiterating remarks Trump made earlier that “nothing’s going to happen” until the two come face to face.

Marco Rubio appeared on Fox News for an interview with Sean Hannity on Thursday.Fox News
Rubio asserted that a Trump meeting with Vladimir Putin was crucial to ending the Ukraine war.AP

“There’s been talks, there’s been negotiations, there’s been trips and meetings — but in the end, I think we’ve reached the conclusion, rightfully so, as the president has, that the only way this is going to happen, if it has a chance to happen, the only way it happens is, if the president directly engages with Vladimir Putin,” he added.

Rubio, who is leading a US delegation in Turkey for talks — proposed by Putin— aimed at settling the bloodiest European conflict since World War II, lauded Trump as a peace-centric president.

“The president, frankly, is a lover of peace,” the top US diplomat said.

Trump met with Ukrainian President Volodimir Zelensky while both leaders were in attendance for Pope Francis’ funeral.AP

“This is a person that wants to stop wars and prevent wars and end wars. That’s what the president endeavors to do,” Rubio continued.

“I still don’t understand why some would be critical of the president,” he added. “They should be happy that the president of the most powerful nation on earth is a peacemaker who seeks to prevent wars, seeks to end wars, and seeks to stop existing wars.”

“That, I think, is something we should be very proud of.”

Trump, 78, had made ending the war a top objective of his second term’s foreign policy. 

The president, at times, has expressed frustration with both Ukrainian President Volodymyr Zelensky and Putin for the lack of progress toward peace. 

As Rubio noted, Trump told reporters aboard Air Force One Thursday that he doesn’t believe a truce is possible unless he pow-wows with Putin. 

“Nothing is going to happen until Putin and I get together,” he said. 

“He wasn’t going if I wasn’t there,” Trump said of the Russian president’s notable absence in Turkey. 

“I don’t believe anything’s going to happen, whether you like it or not, until he and I get together,” the president added. “But we’re going to have to get it solved cause too many people are dying.”

Zelensky flew to Turkey for the talks but Ukrainian Defense Minister Rustem Umerov represented Kyiv in negotiations after Putin failed to show. 

“After we understood the level of the Russian delegation, we saw that they unfortunately are very unserious about real negotiations,” Zelensky said.

Ukraine is believed to be interested in getting Russia to agree to the US-proposed 30-day cease-fire during the talks in Istanbul. 

Zelensky has also called on the US, Europe and the global south to further sanction Russia if they fail to agree to the long sought-after pause in the conflict.

https://nypost.com/2025/05/15/us-news/rubio-asserts-trump-sitting-down-with-putin-is-only-way-ukraine-war-ends/

Justin Bieber proclaims he’s ‘not among’ Sean ‘Diddy’ Combs’ victims

 Justin Bieber said he was never a victim of accused sex abuser Sean “Diddy” Combs, who helped the young singer break into the music industry when he was just 15 years old — ending his silence on the rumor amid the disgraced mogul’s bombshell sex trafficking trial.

“Although Justin is not among Sean Combs’ victims, there are individuals who were genuinely harmed by him. Shifting focus away from this reality detracts from the justice these victims rightfully deserve,” reps for Bieber, 31, told TMZ in a statement Thursday night.

Multiple sources close to the “Never Say Never” singer told the outlet that Combs, 61, never sexually or otherwise abused Bieber in any capacity — tamping down online speculation in light of Combs’ sex trafficking trial this week.

Justin Bieber addressed Sean “Diddy” Combs in a statement on Thursday.Getty Images

As Combs’ trial in Manhattan federal court continues, celebrity watchers online turned back to several videos of the “Bump, Bump, Bump” rapper and the then-teenage Bieber.

In one of the videos, Combs makes a series of awkwardly phrased comments as the baby-faced Bieber stands awkwardly and increasingly flushed while looking at the camera.

“Right now [Bieber’s] having 48 hours with his boy,” Combs said in a direct address to the camera.

“Where we’re hanging out and what we’re doing cannot really be disclosed,” he said, adding, “For the next 48 hours, he’s with me and we’re gonna go buck full crazy.”

In recent months, concern from fans has grown over the “Yummy” singer’s increasingly ramshackle appearance, flagrant drug use, and close to incoherent social media posts

Bieber’s statement claimed he was not a victim of the rap mogul.WireImage

video from last year showed a pre-arrest Combs briefly meeting with Bieber and exhibiting some odd body language that some online speculators believed was actually a pat-down for hidden wires.

A resurfaced joint interview on “Jimmy Kimmel Live!” has also raised eyebrows.

“He knows better than to be talking about the things that he does with big brother Puff on national television,” Combs said. “Everything ain’t for everybody.”

The former producer for slain rapper Notorious B.I.G. is currently on trial in Manhattan federal court, where prosecutors with the Southern District of New York alleged he engaged in sex trafficking as part of his voracious need for “freak offs.”

A court sketch of Combs as his trial for sex-trafficking began this week.REUTERS
Bieber seen with Diddy’s ex Cassie Ventura, who has taken the stand this week to testify against Combs, in a 2014 photo.FilmMagic
In court Thursday, lawyers for the disgraced mogul claimed that the allegedly highly orchestrated “freak offs” featuring Combs’ then-girlfriend, pop-star Cassie Ventura, were merely part of the couple’s “swingers lifestyle.”

Ventura has claimed that she was drugged, physically abused, raped, and forced to participate in the wild, baby oil-fueled sex romps at the command of Combs.

https://nypost.com/2025/05/15/us-news/justin-bieber-breaks-silence-on-sean-diddy-combs-as-rap-mogul-faces-sex-trafficking-trial/

TriSalus Life Sciences projects 50% revenue growth in Q1 2025

 TriSalus Life Sciences Inc., a medical technology company with a market capitalization of $158 million, reported a robust performance in Q1 2025, with net sales reaching $9.2 million, marking a 42% increase year-over-year. Despite a slight dip in gross margin, the company reported reduced operating losses and announced significant strides in product development and market expansion. The stock price closed at $4.9, reflecting a 3.35% decrease. 

Key Takeaways

  • TriSalus Life Sciences reported a 42% year-over-year increase in net sales.
  • The company reduced operating losses significantly compared to the previous year.
  • Newly launched products and market expansions are expected to drive future growth.
  • TriSalus anticipates at least 50% revenue growth in 2025.

Company Performance

TriSalus Life Sciences demonstrated strong growth in Q1 2025, driven by a strategic focus on expanding its product portfolio and market presence. The company achieved a 10% market share in liver procedures and is making inroads into new clinical applications. This performance is indicative of the company’s aggressive growth strategy in the competitive interventional oncology space.

Financial Highlights

  • Revenue: $9.2 million, up 42% year-over-year and 11% sequentially.
  • Gross margin: 84%, slightly down from 85% in Q1 2024.
  • Operating losses: $7.3 million, an improvement from $11.7 million in Q1 2024.
  • Adjusted EBITDA losses: $5.5 million, compared to $10.4 million in Q1 2024.
  • Cash and cash equivalents: $13 million, with an additional $22 million raised in a private placement.

Outlook & Guidance

TriSalus is targeting at least 50% revenue growth in 2025, driven by new product launches and market expansion. The company is investing in its sales force and clinical applications, although it does not expect to achieve EBITDA or cash flow positivity until early 2026. The focus remains on strengthening clinical evidence and expanding partnerships, particularly for the drug nalatolimod.

https://www.investing.com/news/transcripts/earnings-call-transcript-trisalus-life-sciences-projects-50-revenue-growth-in-q1-2025-93CH-4048084

Anavex Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data


Positive Points

  • Anavex Life Sciences Corp (NASDAQ:AVXL) reported a strong cash position of $115.8 million with no debt, providing a financial runway of approximately four years.

  • The company presented promising open-label extension data for their Alzheimer's treatment, showing significant clinical benefits over three years.

  • Enrollment for the phase two clinical study of AI 371 for schizophrenia was successfully completed, with encouraging preliminary safety and biomarker results.

  • Anavex Life Sciences Corp (NASDAQ:AVXL) expanded its scientific advisory board with the appointment of Professor Doctor Audrey Gabel, enhancing expertise in predictive personalized medicine.

  • The company is actively preparing for potential European market entry, engaging in discussions with potential partners and CROs for distribution and sales strategies.

Negative Points

  • Anavex Life Sciences Corp (NASDAQ:AVXL) reported a net loss of $11.2 million for the quarter, equating to $0.13 per share.

  • Research and development expenses increased slightly to $9.9 million, indicating rising costs in their development pipeline.

  • The timeline for receiving feedback from the European Medicines Agency (EMA) is uncertain, with expectations set for late this year or early next quarter.

  • The schizophrenia trial's focus on safety and biomarker effects may delay comprehensive efficacy data, as it is primarily a preliminary study.

  • There is uncertainty regarding the timeline for revenue generation post-approval in Europe, with logistical challenges potentially impacting the launch.

Q & A Highlights

Q: What is the expected timeline for feedback from the European Medicines Agency (EMA) regarding the Alzheimer's treatment? A: Dr. Christopher Mistling, CEO, stated that they expect feedback from the EMA by the end of this year or early next quarter, following their submission in November last year. They will report the decision in its final form without interim updates.

Q: What are the key inflection points for Anavex Life Sciences in 2025, particularly regarding the schizophrenia study? A: Dr. Mistling highlighted that the phase 2 study in schizophrenia is the first efficacy study of 371, focusing on safety and biomarker effects. The study aims to address unmet needs, especially concerning negative symptoms, and will provide insights into the drug's effect on the brain using validated biomarkers.

Q: Can you elaborate on the duration and structure of the schizophrenia trial? A: Dr. Mistling explained that the schizophrenia trial consists of two parts: Part A with single ascending doses and Part B with a longer duration of 28 days. Part B includes 55 patients randomized to placebo or active arm, providing a more comprehensive picture of the drug's effect.

Q: What preparations are being made for the potential launch of the Alzheimer's drug in Europe? A: Dr. Mistling mentioned that discussions with potential partners and CROs are underway to ensure quick distribution and access to the drug in Europe. They are considering both partnering with a major entity or setting up an independent sales force, depending on what maximizes value.

Q: What are the advantages of oral administration of the Alzheimer's drug for patients and their families? A: Dr. Mistling emphasized that oral administration allows for timely treatment without complex diagnostic procedures, reducing caregiver stress and financial strain. It eliminates the need for frequent hospital visits, benefiting both patients and their families by minimizing logistical challenges.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

https://finance.yahoo.com/news/anavex-life-sciences-corp-avxl-210137221.html